XBL * A subsidiary of Lab Testing Division, WuXi AppTec Inc. WuXi AppTec XBL * A subsidiary of Lab Testing Division, WuXi AppTec Inc. WuXi AppTec
Thursday, January 18, 2018

Biological Services for Immunochemistry and Cell Based Assays Launched at XBL

Plainsboro, NJ, February 02, 2009 - XenoBiotic Laboratories (XBL) has enhanced its capabilities with the addition of two new biological services: immunochemistry and cell-based assays. With the recent acquisition of a state-of-the-art SECTOR Imager 6000 from Meso Scale Discovery (MSD), XBL is offering the premiere electrochemiluminescent (ECL) technology to our biotechnology and pharmaceutical customers. ECL technology provides enhanced sensitivity, wide dynamic range and flexibility over traditional ELISA for the measurement of macromolecules, including and not limited to therapeutic drugs, synthetic peptides, humanized monoclonal antibodies, growth factors, hormones, cytokines, and biomarkers. The multiplexing capability of the MSD technology allows quantitative measurement of multiple analytes or protein biomarkers in a single test sample, which will significantly reduce turn-around time for sample analysis. XBL also offers quantitative macromolecule PK, immunogenicity testing, biomarkers for PD and safety assessment, and other ELISA-based applications. Studies can be conducted at exploratory, non-GLP, or fully GLP compliant levels.

Concurrently, XBL has opened a new laboratory for cell-based assays. Beginning in April, 2009, we will offer functional bioassays to detect neutralizing antibodies that will complement our immunochemistry services. In addition, we will offer a wide range of cell-based assays for drug potency evaluation, alternation of cell signaling pathway and pre-clinical toxicity profiling, including assays to measure cell viability, cell proliferation, apoptosis, and protein phosphorylation.

The launch of these new biological services will enhance XBL's proposition for our clients to seamlessly transfer compound knowledge from discovery to preclinical stage into early-phase clinical research.

The addition of immunochemistry and cell-based assays is another example of XBL's commitment to offer the latest advances in technology to the pharmaceutical and biotechnology industries, and to enhance its core services in the bioanalytical, ADME, and metabolism profiling areas. XBL is FDA and EPA inspected, AAALAC accredited, and NRC and USDA licensed to best serve your research and development needs.

For further information, contact:
Vicky Lai, Ph.D. at vicky_lai@xbl.com or Dennis P. Heller, Ph.D. at dheller@xbl.com or address inquires to xblinfo@xbl.com